Beyond Air Inc - Asset Resilience Ratio
Beyond Air Inc (XAIR) has an Asset Resilience Ratio of 13.65% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Beyond Air Inc (XAIR) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Beyond Air Inc's Asset Resilience Ratio has changed over time. See XAIR equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Beyond Air Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Beyond Air Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.02 Million | 13.65% |
| Total Liquid Assets | $5.02 Million | 13.65% |
Asset Resilience Insights
- Moderate Liquidity: Beyond Air Inc has 13.65% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Beyond Air Inc Industry Peers by Asset Resilience Ratio
Compare Beyond Air Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Dirui Industrial Co Ltd
SHE:300396 |
Medical Devices | 6.89% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Annual Asset Resilience Ratio for Beyond Air Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Beyond Air Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 7.49% | $2.25 Million | $30.06 Million | -33.05pp |
| 2024-03-31 | 40.54% | $23.09 Million | $56.96 Million | +16.21pp |
| 2023-03-31 | 24.33% | $16.72 Million | $68.75 Million | -- |
| 2022-03-31 | 0.00% | $0.00 | $99.20 Million | -- |
| 2020-03-31 | 0.00% | $0.00 | $27.43 Million | -- |
| 2019-03-31 | 69.40% | $6.54 Million | $9.43 Million | -19.37pp |
| 2018-03-31 | 88.77% | $8.30 Million | $9.36 Million | -- |
About Beyond Air Inc
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treat… Read more